Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

652 women (80% postpartum) who received 300 mcg daily doses of quingestanol acetate (W 4540) for an average of 9.6 cycles were observed during a 3-year study conducted by Ramon Sarda Maternal and Children's Hospital of Buenos Aires. Of 16 pregnancies, 6 were attributed to drug failure for a rate of 3.1/100 woman-years. It was found that menstrual cycle length, duration, and amount of flow were consistent with normal cycles. Amenorrhea was observed in 65% of the patients and in 24% of the cycles. 35% of all patients had at least 1 case of intermenstrual bleeding. Spotting was reported in 32% of the patients and in 6% of the cycles. Except for headaches (8% of the cases, 2% of total cycles) no significant side effects were experienced. 92% of the women are still on treatment. Quingestanol acetate (300 mcg daily) was found to be clinically safe and effective for postpartum patients.
 ...
PMID:Evaluation of the contraceptive efficacy of quingestanol acetate (W 4540) when administered as an oral low-dose conraceptive in the puerperium. 455 82

The first 600 cases of a 1200-case study of a monthly contraceptive pill at the Family Planning Clinic at Al-Azhar University Hospital in Cairo are described. The estrogen component, Quinestrol (17 alpha ethinyl estradiol-3-cyclopentyl ether) has prolonged activity. Quingestanol acetate (3 cyclopentyl ether derivative of norethindrone acetate), the progestogen component of the pill, induces withdrawal bleeding, and regulates the cycle. In Group A (96) the first pill was given on day 25 of the cycle to get withdrawal bleeding at the supposed date of the next flow; subsequent pills were given monthly on the same day of each calendar month. In Group B (504) the first pill was given on the first day of the menstrual flow and the second pill after 3 weeks; subsequent pills were given monthly on the same day of each calendar month. Follow-up was for 6 to 12 months. The total number of cycles was 3858. The flow began 6-15 days after taking the pill in 80.4% of the cycles. Treatment cycles were significantly longer than premedication cycles. During contraception the incidence of light flow decreased from 19.6 to 4.19% and the incidence of heavy flow increased from 10 to 12.4%. The mean duration of flow rose from 4.3 to 6.4 days. Percentages of cycles experiencing intermenstrual bleeding and amenorrhea were 5 and 2.6. Dysmenorrhea increased gradually to 20% at the ninth cycle. No significant changes were found in weight, libido, or breasts. Percentages of cycles getting various side effects were nausea and vomiting (6.95), headache (4.57), fatigue (4.05), and discharge (3.02). By the fourth cycle none of the 106 women originally lactating were still doing so. Ignoring pregnancies in the first cycle, when the pill is not yet effective, the pregnancy rate was 2.8/100 woman year. Endometrial biopsies indicated an anti-ovulatory effect after the first cycle. The drop-out rate was 21.3% in the first cycle, but no cases dropped out after the eighth cycle.
 ...
PMID:Pill-a-month as an oral contraceptive. 1225 24